Quantitative analysis for Abivax S.A. (ABVX) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Sell (41.0) (grade D). 39 signals analyzed (33 differentiated alt-data).
ABVX stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-28 | $114.41 | $109.77 | $109.87 |
| 2026-05-08 | $126.74 | $121.21 | $122.74 |
| 2026-05-20 | $121.00 | $114.07 | $119.90 |
| 2026-06-02 | $83.34 | $69.81 | $72.50 |
| 2026-06-12 | $100.90 | $96.21 | $96.55 |
| 2026-06-25 | $93.20 | $87.01 | $92.37 |
| 2026-07-08 | $141.75 | $136.85 | $138.54 |
| 2026-07-20 | $138.32 | $130.85 | $131.50 |
| 2026-07-30 | $125.39 | $119.00 | $124.33 |
| 2026-08-12 | $128.19 | $125.22 | $125.52 |
| 2026-08-24 | $116.22 | $113.30 | $116.15 |
| 2026-09-03 | $116.10 | $112.10 | $114.04 |
How Abivax S.A. stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| ICLR | ICON Public Limited Company | $8.8B | — |
| GRFS | Grifols, S.A. | $6.9B | — |
| CNTA | Centessa Pharmaceuticals plc | $6.2B | — |
| BLCO | Bausch + Lomb Corporation | $5.8B | — |
View all Health Care stocks by valuation and signals →
Abivax S.A. (ABVX) scores Sell (41.0), and the composite conceals a 78-point disagreement between its dimensions. It is strongest on competitive moat at 87, and weakest on analyst consensus at 14 and ML forecast at 9. A stock can carry competitive moat that high while ML forecast sits at 9; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| competitive moat | 87 |
| technicals | 40 |
| analyst consensus | 14 |
| ML forecast | 9 |
StoQuant analyzes 39 signals (33 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Abivax S.A. (ABVX): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/ABVX"><img src="https://stoquant.com/badge/ABVX.svg" alt="Abivax S.A. (ABVX) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.